Supplementation with the probiotic strain Bifidobacterium animalis subsp. lactis BB-12 (BB-12) could be helpful in treating colic in infants, suggest findings from a new trial which have just been published in Alimentary Pharmacology & Therapeutics.
The trial randomised 80 exclusively breastfed infants with colic, who were otherwise healthy, to receive BB-12 (n=40) or placebo (n=40) for 28 days. Parents were asked to administer six drops of the assigned product to the infants once daily.
The authors reported that infants in the BB‐12 group presented a significantly higher reduction in crying duration after 28 days of treatment compared to the placebo group (P<.0001 the duration of daily crying was reduced by more than per cent in who received probiotic with beneficial effects on sleep and stool frequency consistency only infants placebo.>
The authors said the finding provides further evidence of the important role of gut microbiota as a target of intervention against colic. They noted that the trial studied a specific well‐characterised probiotic strain and that these findings cannot be extrapolated for other probiotic strains.